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The epidemiology of Chronic 
Suppurative Lung Disease and 
Bronchiectasis in Children and 
Adolescents
Gabrielle B. McCallum* and Michael J. Binks
Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia
In the modern era, the global burden of childhood chronic suppurative lung disease 
(CSLD) remains poorly captured by the literature. What is clear, however, is that CSLD is 
essentially a disease of poverty. Disadvantaged children from indigenous and low- and 
middle-income populations had a substantially higher burden of CSLD, generally infec-
tious in etiology and of a more severe nature, than children in high-income countries. 
A universal issue was the delay in diagnosis and the inconsistent reporting of clinical 
features. Importantly, infection-related CSLD is largely preventable. A considerable 
research and clinical effort is needed to identify modifiable risk factors and socioeco-
nomic determinants of CSLD and provide robust evidence to guide optimal prevention 
and management strategies. The purpose of this review was to update the international 
literature on the epidemiology, etiology, and clinical features of pediatric CSLD.
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iNTRODUCTiON
Bronchiectasis, a chronic progressive disease of the airways, remains one of the most neglected 
diseases in respiratory health (1). It is characterized by abnormal dilatation of the bronchi caused 
by protracted inflammation (2) and by chronic productive or wet cough (3). A definitive diagnosis 
of bronchiectasis requires a chest high resolution computer tomography (cHRCT) (4), with cases 
otherwise referred to as having chronic suppurative lung disease (CSLD) (5). Bronchiectasis or CSLD 
(from hereafter combined and referred to CSLD) has multiple etiologies and are often associated 
with underlying conditions (e.g., congenital malformation, cystic fibrosis, or immune deficiency) 
(6, 7). However, recurrent acute lower respiratory infections (ALRI) during early childhood, a crucial 
time for lung growth and development, are arguably the common etiology for CSLD, particularly 
among socially disadvantaged children (8, 9).
Globally, the prevalence of CSLD in high-income countries over the last 50 years has declined with 
the introduction of antibiotics, immunizations, improved hygiene, nutrition, and access to medical 
care (10–16). However, a substantial burden of CSLD persists among socially disadvantaged popula-
tions of high-income countries (e.g., Alaskan, Australian, Canadian, Maori, and Pacific Islander 
children) (8, 16–20) with the extent of pediatric CSLD in low- and middle-income countries largely 
Abbreviations: ALRI, acute lower respiratory infection, cHRCT, chest high resolution computed tomography scan, CSLD, 
chronic suppurative lung disease, FTT, failure to thrive, NT, Northern Territory, NZ, New Zealand, Qld, Queensland, 
PCD, primary ciliary dyskinesia, UAE, United Arab Emirates, UK, United Kingdom, USA, United States of America, YK, 
Yukon–Kuskokwim.
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unknown. In recent years, there has been a growing awareness 
of CSLD related to the increased use of cHRCT diagnostics and 
emerging research into the etiology (6), microbiology, immunol-
ogy (21), and clinical management (22), yet, robust epidemio-
logical data remain sparse. Our understanding of the complex 
interplay between the host, pathogens, and the environment is 
largely superficial, and there have been few clinical intervention 
trials among children and adolescents. Here, we provide an 
update on the epidemiology, etiology, and clinical features of 
pediatric CSLD not associated with cystic fibrosis.
GLOBAL iNCiDeNCe OF CSLD
Historical
French physician Rene Laennec first described CSLD in the 
early nineteenth century (23), with the first surgery (24) and 
imaging (25) performed around 100  years later. In the 1930s, 
Roles described the poor prognosis of CSLD patients at the 
time and highlighted the importance of early diagnosis and the 
potential of lobectomy for enhanced survival (26). The benefit 
of surgery over medical management was unclear in several 
subsequent studies (27–30), though a surgical case series of 
CSLD conducted decades later was convincing, particularly for 
children (13). With the introduction of broad spectrum antibiot-
ics in the 1950s, significant reductions in CSLD incidence were 
reported. In the United Kingdom (UK) between 1952 and 1960 
(12), CSLD admissions fell fivefold from 23.8 to 4.9 per 1,000 
total admissions. Similar findings were reported elsewhere in 
the UK (10) and in the United States of America (USA) (11). 
Childhood CSLD became confined to disadvantaged popula-
tions of high-income countries, earning it the label of an “orphan 
disease” (14). Alaskan native children <16 years of age appeared 
vulnerable with a conservatively estimated case prevalence of 
41/100,000 population over the decade 1956–1966, largely in 
the Yukon–Kuskokwim (YK) Delta and with one-third of cases 
associated with tuberculosis infection (16). In the 1960s, the 
prevalence of CSLD among Scottish children (<10 years of age) 
was 10.6/100,000 (27), and in the early 1970s, a substantial bur-
den of CSLD was reported among indigenous children living in 
Central Australia (31). In this study, 83 indigenous children with 
CSLD were identified (60% <2 years of age) from an estimated 
population of around 1,000, despite near complete eradication of 
tuberculosis, measles, and pertussis, previously considered to be 
key etiological pathogens (31). In one of the few African stud-
ies, 70/1,150 patients consecutively admitted to the University 
Hospital in Nigeria with respiratory or cardiovascular disease 
between 1975 and 1979 were diagnosed with CSLD, of which 10 
(14%) were children (32).
In the following section, we review the population incidence 
of pediatric CSLD in the modern era (1980–2016), when immu-
nization and antibiotic interventions control many of the major 
etiological pathogens of the past, including tuberculosis, pertus-
sis, measles, and pneumococcus.
Modern era: 1980–2016
We performed a systematic literature review of the PubMed 
library followed by a bibliography search within all relevant 
articles. The PubMed search terms: (CSLD OR bronchiectasis) 
AND (pediatric OR child OR children OR infant) AND (epide-
miology) yielded 351 articles, which was reduced to 243 when 
confined to non-cystic fibrosis-related bronchiectasis articles 
published since 1990 and performed after 1980, human research, 
and non-review articles written in English. From these, 13 
relevant studies reported CSLD rates: either directly (incidence 
rate) or indirectly (included a bronchiectasis disease numerator, 
an estimate of the population denominator, and an observation 
period). In one New Zealand (NZ) study, age-specific data could 
not be accurately extracted or obtained from the authors and 
were, therefore, excluded (33). A government report capturing 
similar national NZ CSLD data was included in its place (34).
In our defined modern era (1980–2016), the burden of 
childhood CSLD remains difficult to characterize. In the 
1980–1990s, wheezing and persistent cough were often consid-
ered clinical features of asthma and not related to CSLD. Thus, 
due to lack of robust evidence, misclassification was likely 
and management (e.g., antibiotics) possibly suboptimal. Peer 
reviewed published burden data were available from only nine 
countries, diagnostic criteria varied, population denominators 
were often approximate, and incidence/prevalence data were 
inconsistently reported. Further, hospital-based studies utiliz-
ing International Classification of Diseases coding to identify 
CSLD (ICD8 518, ICD9 J494, and ICD10 J47) were common. 
ICD coding does not provide radiological information (though 
several studies confirmed cHRCT diagnosis via medical records 
or subsequently performed cHRCT) nor distinguish between 
primary and repeat admissions (exacerbations), which must 
be ascertained by diagnosis in conjunction with date of pres-
entation. While rare in most high-income countries, in some 
settings (e.g., Australian indigenous children) as many as 1 in 
136 children have a new case of CSLD detected annually (8). 
Despite limitations in data accuracy, the trends toward higher 
rates of CSLD among socially disadvantaged populations were 
clear though perhaps partially attributed to enhanced surveil-
lance. The collated global epidemiology data are summarized 
in Table 1.
High-income Countries
In most affluent European populations, pediatric CSLD was 
relatively uncommon with average annual rates ranging from 
0.2/100,000 in the UK (37) to 2.3/100,000 in Ireland (38), 
however, in the equally affluent, yet non-European United Arab 
Emirates (UAE; 13.3/100,000) (36) and largely non-European NZ 
(15.0/100,000) (34), CSLD was more common. The indigenous 
Arabic children in the UAE children were predominantly from a 
wealthy social demographic with almost universal immunization 
coverage, therefore, the surprisingly high rates may be related to 
an inherited predisposition or to moderate levels of educational 
attainment. In NZ, the high national rate is a reflection of the 
high proportion of less affluent Maori and Pacific Islander people 
(~40%) for which there is a well-established susceptibility to 
respiratory infection (19, 43, 44). In this particular report by 
Simpson (34), CSLD cases were not reported by ethnicity. As 
clarified in the next section, the annual rate was much lower 
(1.5/100,000) for NZ people of European heritage (18, 20).
TABLe 1 | Burden of CSLD in children.
Reference Pub. 
year
Country Region Population era Time 
(years)
Male: 
female
Age 
(years)
Data source Given or 
extrapolatedh 
Be cases (n)
Chest high 
resolution 
computer 
tomography 
(n)
Median 
age at 
diagnosis 
(years)
Given or rate 
extrapolatedb 
population 
denominator 
(n)
Alternativeb 
population 
denominator 
estimate (n)
Given or 
extrapolatedi 
average 
annual 
incidence
Affluent countries
Saynajakangas 
et al. (35)
1998 Finland National Non-specific 1983–
1992
10 31:16 <14 Hospital admissions 
(ICD8 518; ICD9 494)
47 na na 959,184a 944,253c 
(1983–
1992avg)
0.5
Dawson and 
Bakalinova (36)
1997 UAE Al Ain Arabic 1994–
1995
1 na 1–13 Pediatric hospital clinic 12 na na 90,000 nr 13.3i
Laverty et al. 
(37)
2008 UK All 
countries
Non-specific 2006–
2007
1 na <16 Electronic registry 23 na na na 11,644,416c 
(2006)
0.20i
Zaid et al. (38) 2010 Republic 
of 
Ireland
National Non-specific 2006 1 na <18g Pediatrician 
surveillance
24h 24 na na 1,040,623c 
(2006)
2.3
Simpson et al. 
(34)
2014 NZ National Non-specific 2009–
2013
5 na <15 Hospital admissions 
(ICD10 J47)
681 na na 908,000 1,000,160c 
(2013)
15.0
Disadvantaged populations
Flynn (19) 1994 Fiji Suva Native Fijian 1985–
1989
4 na 5–14 Hospital admissions 
(ICD9 494)
25 na na 89,285a 78,960d 
(1994)
7.0j
Singleton et al. 
(16)
2000 USA Alaska 
(YK 
Delta)
Alaskan 
natives
1980–
1990
10 na <14g Statewide registry and 
hospitalizations
~91h 28+ na na 6,500e (1990) ~140j
Edwards (18) 2003 NZ Auckland TOTAL
Pacific Island
Maori
Europeans
Other
1998–
2000
3 36:24 1–17 Hospital admissions 60
33
15
8
4
60 8.0 354,000a
60,180
63,720
173,460
56,640
307,600f
57,000
50,600
167,000
33,000 (2001)
5.7j
18.3
7.9
1.5
2.4
Chang et al. (8) 2003 Australia Central Indigenous 2000–
2002
2 31:34 ≤15 Hospital admissions 
(ICD10 J47) + medical 
record review
65 59 5.4 4,422a nr 735.0i
Twiss et al. (20) 2005 NZ National TOTAL
Pacific Island
Maori
European
Other
2001–
2002
2 28:37 ≤15 Pediatrician 
surveillance
63
32
19
18
3
63 5.2 851,351a
89,887
197,916
600,000
62,500
877,200f
100,000
216,100
652,600
69,000 (2001)
3.7
17.8
4.8
1.5
2.4
O’Grady et al. 
(39)
2010 Australia NT Indigenous 1999–
2004
5 7:3 <1 Hospital admissions 
(ICD10 J47)
10 na 0.7 9,295 nr 118
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Reference Pub. 
year
Country Region Population era Time 
(years)
Male: 
female
Age 
(years)
Data source Given or 
extrapolatedh 
Be cases (n)
Chest high 
resolution 
computer 
tomography 
(n)
Median 
age at 
diagnosis 
(years)
Given or rate 
extrapolatedb 
population 
denominator 
(n)
Alternativeb 
population 
denominator 
estimate (n)
Given or 
extrapolatedi 
average 
annual 
incidence
Das and 
Kovesi (17)
2014 Canada Qikiqtani, 
Nunavut
Indigenous 1998–
2011
13 na <17 Medical record review 17 17 5.6 8,415a nr 15.5i
Janu et al. (40) 2014 Australia Central 
Qld
Indigenous 2007–
2011
5 4:3 <2 Hospital admissions 
(ICD10 J47) + medical 
record review
7 7 0.5 341a nr 410
Incidence standardized to an annual average per 100,000 children. Repeat bronchiectasis episodes were excluded from hospital data where possible in an attempt to focus on the index cases. Most studies reported a study 
observation period rather than actual person–time of observation censored at the bronchiectasis event. Censoring of these rare events in large populations would have had little effect on incidence. Given population denominators were 
included where possible, otherwise arate extrapolated population denominators were calculated (from numerator and rate).
bAlternative population denominators were sourced where necessary and to reaffirm rate estimated population denominators.
cWorld Population Prospects: the 2015 Revision. United Nations, Department of Economic and Social Affairs, Population Division. http://populationpyramid.net (accessed 2/11/2016).
dFiji census data, 1986. http://www.statsfiji.gov.fj/statistics (accessed 2/11/2016).
eStatus of Alaskan Natives Report (41) and Alaska Native Health Status Report (42).
fStatistics New Zealand. http://nzdotstat.stats.govt.nz (accessed 7/11/2016).
gEstimated age range based on a smaller bronchiectasis study sub-population than that which the rate calculation was based on.
hExtrapolated numerator calculated from the given or estimated denominator and the given rate.
iExtrapolated average annual incidence calculated from the numerator, given or estimated denominator, and the study observation period.
jExtrapolated average annual incidence rate in this case was per 100,000 children born between 1980 and 1990 and followed until 1998.
na, not available; nr, not relevant.
~, data estimated from a graph and unable to be confirmed by the authors.
Bold indicates the population denominator matched to the incidence calculations.
Italics highlight sub-category data that are not mutually exclusive (i.e., sums to greater than the total).
TABLe 1 | Continued
4
M
cC
allum
 and B
inks
E
pidem
iology of C
S
LD
 in C
hildren
Frontiers in P
ediatrics | w
w
w
.frontiersin.org
February 2017 | Volum
e 5 | A
rticle 27
5McCallum and Binks Epidemiology of CSLD in Children
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 27
Socially Disadvantaged Populations 
of High-income Countries
The highest reported pediatric CSLD rates occur among socially 
disadvantaged indigenous populations of the Pacific Islands 
(19), NZ (18, 20), Australia (8, 39, 40), Alaska (16), and Canada 
(17). In the Pacific, Native Fijian children (5–14  years of age) 
had over 20-fold more CSLD hospital admissions (7.0 versus 
~0.3/100,000) than their Indo-Fijian counterparts between 
1985 and 1989 (19). Two NZ studies spanning 1998–2002, one 
examining national CSLD cases reported by pediatricians (20) 
and the other CSLD hospital admissions in Auckland (43), dem-
onstrated the disproportionate average annual incidence among 
Maori (4.8–7.9/100,000) and Pacific Islander (17.8–18.3/100,000) 
compared to European children (1.5/100,000). This disparity is 
directly related to child poverty. In NZ, substantially more Maori 
and Pacific Islander families live in poor (28–34%), overcrowded 
(25–50%) households with high unemployment rates (15%) 
compared to European families (16, 5, and 5%, respectively) (34). 
Similarly, in Australia and Alaska, CSLD is largely confined to 
indigenous children.
In the early 2000s, the average annual incidence of cHRCT 
confirmed bronchiectasis among indigenous children living in 
Central Australia was high at 735/100,000 (8). Almost all chil-
dren (95%) had pneumonia at an early age (median 6 months) 
and nearly two-thirds had concurrent chronic suppurative otitis 
media (8). Two further hospital-based studies have investigated 
CSLD among Australian indigenous children. The first study, a 
historical cohort examining the entire indigenous population of 
Australia’s Northern Territory (NT) (both Central and Northern 
Australia from 1999 to 2004) showed an average CSLD incidence 
of 118/100,000 child-years in the first 12 months of life (39). One 
in five of these infants were also hospitalized with an ALRI. The 
early burden of respiratory illness is of particular concern in this 
region. The second study, a retrospective chart review conducted 
during 2007–2011 at the Mount Isa Base Hospital in Queensland 
(Qld), demonstrated an average annual incidence of 410/100,000 
in children <2 years of age (40).
Alaskan Natives are also historically at high risk of CSLD. In a 
conglomeration of CSLD data from the YK Delta region (collated 
from a state-wide registry, historical and current patients of YK 
Delta Regional Hospital, or Alaska Native Medical Center), the 
average annual incidence of CSLD among children born between 
1980 and 1990 (the review defined modern era) was 140/100,000 
(16); equivalent to the incidence reported among the same 
population born in the 1940s (16). For a similar population, the 
Inuit children of Nunavut, Canada, the average annual incidence 
(1998–2011) of pediatric cHRCT confirmed bronchiectasis 
ascertained via health record reviews was lower but also substan-
tial at 15.5/100,000 (17).
Nationally in NZ (20), and among indigenous children of 
Australia (8), Alaska (16), and Canada (17), CSLD was diagnosed 
at around 5 years of age. In Auckland though, the age was slightly 
older at 8  years (18) and under 2  years of age for Australian 
indigenous infants (39, 40). Common to disadvantaged popula-
tions of high-income countries, was low socioeconomic status, 
inadequate and overcrowded housing, complex environmental 
and social issues, limited access to health care, frequent exposure 
to camp or cooking fires, high smoking rates, and almost a uni-
versal history of early infant pneumonia and/or recurrent ALRIs 
(8, 16–20, 39, 40). In affluent countries, CSLD is more frequently 
associated with non-infectious etiology (see “Etiology”).
Published pediatric CSLD data (etiological, management, 
diagnostic, etc.) are widespread. Countries including Turkey 
(45–48), Saudi Arabia (49), Taiwan (50), Malaysia (51), Tunisia 
(52), Italy (53, 54), and England (55) have published excellent 
research (etiological, management, diagnostic, etc.), however, 
population-incidence could not be accurately elucidated or was 
not the focus of these research articles. We did not identify any 
incidence data among low- to middle-income countries.
CSLD-ReLATeD MORTALiTY
There are limited data on CSLD mortality in the pediatric popula-
tion. More deaths occur in adults. In Central Australia, a hospital 
record review showed that 34.2% (41/120) of indigenous adults 
diagnosed with CSLD 2001–2007 died during that same period. 
Most had a history of pneumonia, nearly half were diagnosed in 
childhood and the median age of death was 42.5 years (56). A 
study in England and Wales showed that only 0.2% (12/5,745) 
of total CSLD deaths recorded between 2001 and 2007 occurred 
among children aged <14 years (57). Whereas, a NZ audit of an 
electronic CSLD database (1991–2006), found that 7% (6/91) 
of children diagnosed with CSLD (median age 7.3  years) died 
during follow-up (median follow-up 6.3  years) (58). A more 
recent study in India identified 80 children (mean age 9.6 years) 
with CSLD via medical record reviews. Among 62 children who 
were prospectively followed for 1  year, 5 (11%) died. To avoid 
premature death from CSLD in both children and adults, it is vital 
to intervene as early as possible.
eTiOLOGY AND CLiNiCAL 
MANiFeSTATiONS OF PeDiATRiC CSLD
A systematic literature review of the PubMed library using the 
search terms: (CSLD OR bronchiectasis) AND (pediatric OR child 
OR children OR infant) and restricted by time (post 1990), type 
(non-review), language (English only), and availability, yielded 
1,163 articles. Further screening to exclude cystic-fibrosis, HIV 
related, surgical, small (<10 CSLD cases), overlapping, or biased 
CSLD populations refined the list to 28 articles (Table 2). From 
these publications, 26 contributed etiology (Table 3) and 27 clini-
cal manifestation data (Table 4).
Demographics
The 26 studies of pediatric CSLD encompassed 2,103 children 
from 15 countries around the world; 13 high-income (including 
studies within disadvantaged sub-populations) and 13 low- and 
middle-income countries (Table 2). The age of symptom onset 
varied significantly among the studies (range 0–16  years) but 
was consistently present many years prior to a diagnosis of CSLD 
[Table 2; mean/median differences ranging from 0.8 to 7 years 
(Table 2)]. Some of the earliest reported symptoms were among 
TABLe 2 | Demographics of CSLD from pediatric studies.
Reference Country Region era N M:F Age of onset of first respiratory 
symptoms in years, median 
(range)
Age at diagnosis of 
bronchiectasis in years, 
median (range)
High-income countries
Nikolaizik and Warner (59) UK London 1994 41 na na na
Li et al. (60) UK London 1986–2002 136 65:71 na na
Kapur et al. (61) Australia Qld 1992–2009 113 64:49 na 5.3 (range 2.7–7.9)
Eastham et al. (55) UK Newcastle 1996–2002 93 62:31 1.1 (0–16) 7.2 (1.6–18.8)
Zaid et al. (38) Ireland Dublin 1996–2006 92 42/50 3.9 (1–12) 6.4 (1.5–13)
Santamaria et al. (54) Italy Naples 2001–05 105 50:55 0.5 (0.08–8.5) 7 (0–14.4)
Socially disadvantaged populations of high-income countries
Singleton et al. (16) Alaska Alaska (YK delta) 1998 46 na 0.4 (0–4.8) 4.8 (1–15)
Edwards et al. (18) NZ Auckland 1998–2000 60 36:24 1 (0–14) 8 (na)
Chang et al. (8) Australia Central 2000–02 59 29:30 0.5 (0–10) 5.4 (0.7–15)
Twiss et al. (20) NZ National 2001–02 65 28:37 2.3 (0–14) 5.2 (0.5–15)
Singleton et al. (9) Australia NT, SA, Qld 2004–10 97 55:39 0.31 (0–3.9) na
USA Alaska (YK delta) 2004–10 41 22:19 0.2 (0–0.8) na
NZ Auckland 2008–10 42 25:17 0.5 (0.1–4.2) na
Munro et al. (58) NZ National 2011 91 49:50 na 7.3 (0.9–16)
Das and Kovesi (17) Canada Qikiqtani, Nunavut 2015 17 na na 5.7 (1.6–15.6)
Low- and middle-income countries
Karadag et al. (47) Turkey na 1987–2001 111 56:55 2.5 ± 2.7b 7.4 ± 3.7b
Karakoc et al. (45) Turkey Southern 1993–99 23 13:10 na 6.2 ± 3.6b
Lai et al. (50) Taiwan Northern 1991–2001 29 12:17 na na
Bouyahia et al. (52)a Tunisia Tunis 1994–2006 41 na ~3.1 (na)b 5.8 (0.5–14)
Banjar (49) Saudi Arabia Riyadh 1993–2005 151 75:76 2.3 ± 2.2b 7.3 ± 4.1b
Koh et al. (62) Korea Seoul 1995–96 25 14/11 na na
Kim et al. (63) Korea Seoul 1999–2008 92 47/45 na 7.6 (0.2–18)
Dogru et al. (46) Turkey Ankara na 204 105:99 2.3 ± 2.2b 8 (na)
Babayigit et al. (48) Turkey Izmar 2003–08 66 44/22 na na
Nathan et al. (51) Malaysia Kuala Lumpur 2004–12 60 43/17 0.5 (0–8) 1.3 (0.2–11)
Kumar et al. (64) India New Dehli 2006–13 80 50/30 na 9.6 (2–15)
Gokdemir et al. (65) Turkey Istanbul 2011–12 47 21/22 3.4 ± 3.3 na
Bahali et al. (66) Turkey Istanbul 2013 76 32/44 5.1 ± 4.6 na
Adapted from Kapur et al. (67) and Brower et al. (6) and additional studies found (as able).
aUnable to access full article.
bmean ± SD.
na, not available or not described.
~, estimated from provided data.
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indigenous infants from Australia (0.3years) (8), and Alaska 
(0.2 years) (9), and New Zealand (0.5 years) emphasizing the early 
origins of CSLD in high-risk children. Interestingly, Malaysian 
(low and middle income) and Italian (high income) children had 
a similar age of symptom onset (0.5 years). Thus, early symptom 
identification is essential to preventing CSLD progressing and 
long-term decline in lung function (68–70).
As with studies reporting incidence (several of which overlap), 
the demographic, etiological, and clinical data varied in their 
nature relating to differences from study design, study era (e.g., 
clinical reporting) and the age at diagnosis of children involved 
(e.g., unable to perform lung function <4 years).
etiology
Chronic suppurative lung disease is the end result of chronic 
airway inflammation that is driven by persistent infection (2). As 
such, the natural history of CSLD depends largely on the sus-
ceptibility to both acute and chronic infection (71). Historically, 
congenital malformations, cystic fibrosis, immune deficiency, 
and aspiration are common antecedents (5), although a primary 
cause is not always identified. Further, measles, tuberculosis, and 
pertussis (27, 72), once the most common causes of CSLD may be 
less important today in the wake of advances (5) in vaccinations, 
antibiotics, and access to health care (67). Reviews of CSLD etiol-
ogy from pediatric cohorts have been published in 2011 (67) and 
2014 (6). Using a systematic search, we further updated the etiol-
ogy literature, which remains similar as previous reviews and is 
briefly summarized below (Table 3) (17, 38, 48, 51, 58, 61, 63–66).
Less than half of the CSLD reported in high-income countries 
(4–35%) (38, 54, 55, 59–61, 73) and low- and middle-income 
countries (10–40%) (45–52, 62, 63) was identified as postinfec-
tious; yet, a history of early infant pneumonia and/or recurrent 
ALRIs was almost universally common to indigenous children of 
Alaska (93%) (16), Australia (90%) (8), and Canada (94%) (17). 
A separate case-control study in Central Australia also found a 
strong relationship between severe recurrent pneumonia in early 
childhood and development of CSLD (74). In the South Korean 
study by Kim et al., 89% (17/19) children with infectious etiology 
TABLe 3 | etiology of CSLD from pediatric studies.
Postinfection (%) immune deficiency 
(%)
Primary ciliary 
dyskinesia (%)
Congenital 
malformations (%)
Aspiration (%) idiopathic (%) Other (%)
High-income countries
Nikolaizik and Warner (59) 32 27 17 15 5 2 2
Li et al. (60) 4 34 15 4 18 26 0
Eastham et al. (55)b 35 26 1 9 5 18 14
Zaid et al. (38) 17 22 9 1 22 32 3
Kapur et al. (61) 12 12 2 na 11 55 8
Santamaria et al. (54) 7 10 24 na 4 55 0
Socially disadvantaged populations of high-income countries
Singleton et al. (16) 93 na na na 4 na na
Edwards et al. (18) 25 12 0 na 10 50 3
Chang et al. (8) 90 3 0 1 5 0 2
Twiss et al. (20) 22 6 0 0 6 54 11
Munro et al. (58) 23 9 na na na 45 23
Das and Kovesi (17) 94 0 0 na 6 na 12
Low- and middle-income countries
Karadag et al. (47) 30 15 6 3 4 38 4
Karakoc et al. (45) 35 17 13 na na na 34c
Lai et al. (50) 28 10 3 3 7 31 18
Bouyahia et al. (52)a 10 10 10 na na 48 22c
Banjar (49) na 18 11 7 10 40 14
Koh et al. (62) 24 na 24 na na 52 0
Kim et al. (63) 21 9 4 na na 14 65d
Dogru et al. (46) 16 5 12 na 3 49 15
Babayigit et al. (48) 21 8 6 3 9 33 17
Nathan et al. (51) 40 7 na 10 na 18 na
Kumar et al. (64) 24 6 15 4 3 36 na
Gokdemir et al. (65) 19 19 26 na 2 33 na
Bahali et al. (66) 16 4 20 na na 53 8
Adapted from Kapur et al. (67) and Brower et al. (6).
aUnable to access full article.
na, not available or not described.
Etiology is described where available.
bMultiple etiologies occurred in some children, therefore, the sum is >100%.
cIncludes cystic fibrosis
dBronchiolitis obliterans (33%) and interstitial lung disease (17%) were common.
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had tuberculosis (63). Taken together, these findings reinforce the 
notion that the high burden of CSLD among indigenous children 
is related to substandard living conditions and is essentially 
preventable.
In affluent European populations where CSLD is less common, 
immune deficiency was identified in a larger proportion of cases 
(10–34%) (38, 54, 55, 59–61, 73) than among indigenous popula-
tions (0–12%) (8, 16–18, 20, 58) and in low- and middle-income 
countries (4–19%) (45–52, 62–66), where acute respiratory 
infections are endemic and CSLD is more common. Other main 
differences highlighted in Table 3 were the higher proportion of 
children with primary ciliary dyskinesia (PCD) in high- and low- 
and middle-income countries (1–24 and 3–26%, respectively) 
(38, 45–52, 54, 55, 59–63, 73) compared to indigenous children 
where PCD was not reported (8, 16–18, 20, 58). Despite improved 
diagnostics and case management globally, the proportion of 
CSLD cases with unknown etiology was relatively consistent 
(0–55%; Table  3) apart from in London (2%) (59) and among 
indigenous children (0%) where most cases were accounted for 
(8, 16). It is likely that previous infections play more of a role 
in the development of CSLD than is currently known. This is of 
particular concern in low- and middle-income countries where 
children with recurrent respiratory infections often have limited 
access to medical care. Even more concerning is that the actual 
burden of CSLD in these countries is largely unknown.
CLiNiCAL FeATUReS AND OUTCOMeS
In this update of the literature surrounding clinical features of 
CSLD, importantly, we have included the largest prospective 
international multicenter study for CSLD in children (9, 75). The 
most comprehensive clinical data in this section are recorded 
among indigenous populations and low- and middle-income 
countries (summarized in Table 4).
Clinical features of CSLD differ depending on the extent of 
the disease. In CSLD, recurrent wet or productive cough is prob-
ably the earliest and most important symptom to recognize and 
investigate, although it should be noted that young children do 
not readily expectorate (3). Despite the importance of cough in 
respiratory health, this was only specifically reported in 59% 
TABLe 4 | Clinical features reported in children with CSLD.
Cough 
(%)
wheeze 
(%)
Chest 
deformity 
(%)
Clubbing 
(%)
Hemoptysis 
(%)
Failure 
to thrive 
(FTT) 
(%)
Fev1% 
predicted, 
median (range)
FvC% predicted, 
median (range)
Chest 
pain 
(%)
Dyspnea 
(%)
High-income countries
Nikolaizik and Warner (59) na na na na na na na na na na
Li et al. (60) 35 10 na na na 4 71 (15–133) 77 (14–22) na na
Kapur et al. (61) na na na na na na na na na na
Eastham et al. (55) na na na na na na na na na na
Zaid et al. (38) na na na na na na na na na na
Santamaria et al. (54) na na na na na na 95 (26–144) 96 (30–132) na na
Socially disadvantaged populations of high-income countries
Singleton et al. (16) na na na na na 17 na na na na
Edwards et al. (18) na na 60 52 na 8 69 (36–110)b 86 (33–109)b na na
Chang et al. (8) 100c na 60 26 na 73 66.2 (38–98) 70.2 (40.2–110) na na
Twiss et al. (20) 40 na na na na na 77 (na) 85 (na) na na
Singleton et al. (9) 50 7 14 10 na 82 na na na 30
75 41 18 5 na 95 na na na 58
52 17 57 45 na 74 na na na 26
Munro et al. (58) na na 42 41 na 15 66 (18–116)b 72 (17–123)b na na
Das et al. (17) 59 na na na na 12 78 (63–108) na na na
Low- and middle-income countries
Karadag et al. (47) 97 47 15 41 10 na 63.3 (22.1)b 67.3 (23.1)b na 50
Karakoc et al. (45) 91 48 na na na na 68.45 (13.70)b 70.34 (9.56)b na 57
Lai et al. (50) 93 35 na 21 41 na 67.6 (43.8)b 82.5 (39.1)b na 10
Bouyahia et al. (52)a na na 27 27 5 na na na na 34
Banjar et al. (49) >66 >66 na 33 5 >66 na na na na
Koh et al. (62) 28 28 na na na na 83 (7)b na na 28
Kim et al. (63) 50 20 na 4 8 na 63 (na) 71 (na) 3 25
Dogru et al. (46) 83 na 1 13 4 46 na na na 9
Babayigit et al. (48) 100 20 5 23 5 27 na na na na
Nathan et al. (51) na na na na na na 52 (32–76) 58 (37–76) na na
Kumar et al. (64) 96 53 na na 16 10 na Na 43 na
Gokdemir et al. (65) na na na na na na 79.8 (20.6)b 80.0 (17.8)b na na
Bahali et al. (66) na na na na na na 72.0 (21.9)b 76.4 (20.0)b na na
Adapted from Kapur et al. (67).
aUnable to access full article. Signs and symptoms overlap often totaling >100%.
bMean ± SD and/or range.
na, not available or not described; FEV1, forced expiratory volume in first second; FVC, forced vital capacity
cStudy inclusion specifically >4 months daily moist and/or productive cough. FTT was inconsistently defined. In the Singleton study (9), FTT was reported as ≤2 SD below norm.
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(16/27) of studies, though we acknowledge in many studies, it 
may have been assumed or captured in other scoring algorithms. 
Low- and middle-income countries consisting of Turkey [7% 
(47), 91% (45), and 100% (48)], India [96% (64)], and Taiwan 
[93% (50)] and the indigenous cohorts of Alaska [75% (9)], 
Australia [100% (8)], and NZ [52% (9)] reported high rates of 
cough. Under-appreciating the importance of cough may delay 
diagnosis and treatment, which can lead to a decline in lung func-
tion and poorer long-term prognosis (76). Likewise, cough is an 
important clinical feature of CSLD exacerbations (1).
In low- to middle-income countries, the proportion of CSLD 
children presenting with wheeze ranged from 20% in Tunisia (48) 
and South Korea (63) to 66% (49) in Saudi Arabia, though it was 
unclear whether all 66% of the Saudi children had wheeze as it 
co-reported with other symptoms. The only high-income country 
reporting wheeze was the UK where 10% of children were identi-
fied. Interestingly, in the multicenter study of indigenous children 
(9), Alaskan natives had a much higher percentage of wheezing 
(41%) than either indigenous children of Australia (7%) or Pacific 
Islander and Maori children of NZ (17%). This correlated with 
an earlier study that showed both Alaskan native children with 
(65%) and without (37%) CSLD had higher rates of wheeze (77). 
It is likely that there are different underlying susceptibilities to 
and clinical manifestations of CSLD across population groups, 
but further exploration is needed to further understand these 
relationships.
Inadequate nutrition (macro and micro) is another factor that 
can increase the risk of developing and/or worsening CSLD by 
compromising innate and adaptive immunity (78), which can 
have long-term consequences (67). As an example, sufficient 
vitamin D is known to be important for regulating immune 
responses to respiratory pathogens (79). Among indigenous 
Australian children, deficiency is associated with an increased 
risk of hospitalization for respiratory infection (80). A typical 
feature of suboptimal energy and protein intake is failure to 
thrive (FTT), which was reported just over one-third of studies. 
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Not surprisingly, FTT was most frequent in socially disadvan-
taged populations; indigenous children from Australia (73–82%) 
(8, 9), Alaska (95%), NZ (74%) (9), and low- and middle-income 
countries of Turkey (46%) (46) and Saudi Arabia (66%) (49).
Currently, cHRCT (the gold standard) and pulmonary func-
tion measurements are the most frequently used objective tools 
used to assess CSLD. Abnormal lung function over time predicts 
poor quality of life score (81–83). The percent predicted forced 
expiratory volume in 1  second (FEV1) reported across studies 
varied, but was lower among children from indigenous (8, 18) 
and low- and middle-income countries (8, 18, 47, 62) than for 
children from high-income countries (54–61, 63–72) suggesting 
more severely affected lung function (Table 4).
Since the previous review by Kapur et al. (67), a further two 
studies (17, 63) reporting lobar involvement (cHRCT) were 
identified, making 15 studies in total (8, 16–18, 20, 38, 45–50, 54, 
55, 63). Multi-lobar involvement was reported in all 15 studies 
and was most common in Taiwan (50), NZ (18), Canada (17), 
and in Saudi Arabia (49). The number of affected lobes varied 
between studies. The left lower lobe (80%) and right lower lobe 
(60%) were most commonly affected. Whether multi-lobar 
involvement relates to clinical severity and poorer outcomes 
remains uncertain.
In more advanced CSLD, clinical features include chest wall 
deformity, digital clubbing, hemoptysis, and dyspnea. Again, these 
markers were common to indigenous populations and low- and 
middle-income countries (Table 4). A further feature, chest pain, 
was reported in two studies from Seoul (3%) (63) and India (43%) 
(64). It is possible that chest pain relates to a delayed diagnosis 
of CSLD (median age 7.6 years in Korea and 9.6 years in India) 
again emphasizing the need for earlier symptom surveillance and 
diagnosis to improve clinical outcomes for children with CSLD. 
In the longer term, complications associated with CSLD extend 
beyond the respiratory system including cardiovascular disease 
an area requiring further investigation (84).
While there are limited long-term clinical data, these studies 
indicate that children with CSLD have different clinical manifesta-
tions across populations. These data also highlights that children 
from socially disadvantaged groups (e.g., indigenous populations 
and low- and middle-income countries) appear to have more 
extensive clinical features and greater propensity for poorer long-
term outcomes than those from high-income countries.
PReveNTiON AND MANAGeMeNT
Despite the high global burden of respiratory diseases, only 
a small percentage of research and development funding and 
resources are devoted to these conditions (71, 85). To prevent 
CSLD, a multidisciplinary approach is required beginning in the 
antennal period continuing throughout childhood. Key strategies 
include immunizations, improved hygiene, nutrition, and educa-
tion (that is culturally appropriate) to improve health-related 
outcomes for children with CSLD (9, 86). Other fundamental 
factors to consider are exposure to tobacco, camp fire, biomass 
fuels, and other environmental air pollutants, overcrowding, 
housing quality, and access to running water. Evidence-based 
clinical guidelines have been developed in several settings to 
guide primary and secondary health care (22, 78, 87, 88), yet, 
more robust and consistent evidence from populations across the 
globe is essential. Other papers in this series will focus on the 
management of CSLD in more detail.
FUTURe ReSeARCH
There is a need for more epidemiological research globally to 
clarify the prevalence of CSLD, in particular, for at-risk popula-
tions (e.g., indigenous and low- and middle- income countries). 
Importantly, there are also no long-term prospective studies in 
children to guide clinical care and management into adolescence 
and adulthood. Clinical trials across multiple countries are essen-
tial to further improve interventional and clinical management of 
CSLD. This can only be achieved with substantial investment and 
support from governments and funding bodies.
CONCLUSiON
Once considered an “orphans disease” among high-income 
populations, this review reinforces that CSLD remains a disease of 
poverty, common among children from indigenous populations 
and low- and middle-income countries. Delayed diagnosis was 
common as was severe disease. Despite the fact that the burden 
of CSLD in these settings was primarily related to early prevent-
able infections, this condition is neglected globally in terms of 
research priority and funding. To improve the respiratory health 
of disadvantaged children, a concerted international effort is 
needed to determine and understand the burden of pediatric 
CSLD and to provide a solid evidence base for future clinical care 
and management.
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